Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01683695 · ClinicalTrials.gov registry record · Phase 1
Safety Study of AMG 557 in Subjects With Lupus Arthritis
A Phase 1 study of Lupus Arthritis, Systemic Lupus Erythematosus, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 13
- Study locations
NCT01683695 is a Phase 1 study of Lupus Arthritis, Systemic Lupus Erythematosus that has completed, run by Amgen. The registered enrollment target is 20 participants. The trial reports 13 study locations across 7 states.
The verdict
NCT01683695, a Phase 1 study of Lupus Arthritis, Systemic Lupus Erythematosus, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, parallel, placebo-controlled, multiple dose study that will enroll approximately 40 systemic lupus erythematosus subjects with active lupus arthritis.
Conditions Studied
Interventions
- DRUG Matching Placebo
- DRUG AMG 557
Study Locations (13)
Other
- Research Site - Odense
- Research Site - Lille
- Research Site - Berlin
- Research Site - Taipei
- Research Site - Birmingham
- Research Site - London
California
- Research Site - Los Angeles
- Research Site - San Leandro
Connecticut
- Research Site - Danbury
New York
- Research Site - Manhasset
New South Wales
- Research Site - St Leonards
Kuala Lumpur
- Research Site - Kuala Lumpur
Sarawak
- Research Site - Kuching
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-06 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01683695
The ClinicalTrials.gov registry entry for NCT01683695 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lupus Arthritis, Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Matching Placebo is the first listed.
NCT01683695 reports 13 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT01683695 about?
NCT01683695 is a clinical study titled "Safety Study of AMG 557 in Subjects With Lupus Arthritis". This is a multicenter, randomized, double-blind, parallel, placebo-controlled, multiple dose study that will enroll approximately 40 systemic lupus erythematosus subjects with active lupus arthritis.
What is the current status of trial NCT01683695?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2012-06. Estimated completion is 2016-03.
What conditions does trial NCT01683695 study?
This clinical trial studies the following conditions: Lupus Arthritis, Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT01683695?
The interventions under investigation include: Matching Placebo (DRUG), AMG 557 (DRUG).
Who is sponsoring clinical trial NCT01683695?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01683695 being conducted?
This trial has 13 study locations across California, Connecticut, New York, New South Wales, Kuala Lumpur. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.